Xamoterol hemifumarate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562251

CAS#: 73210-73-8

Description: Xamoterol hemifumarate is a third generation specific adrenergic ß1 receptor partial agonist.


Price and Availability

Size
Price

Size
Price

Size
Price

Xamoterol hemifumarate is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 562251
Name: Xamoterol hemifumarate
CAS#: 73210-73-8
Chemical Formula: C36H54N6O14
Exact Mass:
Molecular Weight: 794.85
Elemental Analysis: C, 54.40; H, 6.85; N, 10.57; O, 28.18


Synonym: Xamoterol hemifumarate; ICI-118587 hemioxalate; ICI 118587 hemioxalate; ICI118587 hemioxalate;

IUPAC/Chemical Name: (R)-N-(2-((2-hydroxy-3-(4-hydroxyphenoxy)propyl)amino)ethyl)morpholine-4-carboxamide hemifumarate

InChi Key: QEDVGROSOZBGOZ-MZQXSLHISA-N

InChi Code: InChI=1S/2C16H25N3O5.C4H4O4/c2*20-13-1-3-15(4-2-13)24-12-14(21)11-17-5-6-18-16(22)19-7-9-23-10-8-19;5-3(6)1-2-4(7)8/h2*1-4,14,17,20-21H,5-12H2,(H,18,22);1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*14-;/m11./s1

SMILES Code: OC1=CC=C(OC[C@@H](CNCCNC(N2CCOCC2)=O)O)C=C1.OC3=CC=C(OC[C@@H](CNCCNC(N4CCOCC4)=O)O)C=C3.O=C(O)/C=C/C(O)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Cruickshank JM. Beta-blockers and heart failure. Indian Heart J. 2010 Mar-Apr;62(2):101-10. Review. PubMed PMID: 21180298.

2: Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol. 2007 Aug 9;120(1):10-27. Epub 2007 Apr 12. Review. PubMed PMID: 17433471.

3: Tsoi C, Swedmark S. Sulfation in dog. Curr Drug Metab. 2005 Jun;6(3):275-85. Review. PubMed PMID: 15975044.

4: Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for reversible airway disease. Cochrane Database Syst Rev. 2002;(1):CD002992. Review. Update in: Cochrane Database Syst Rev. 2002;(4):CD002992. PubMed PMID: 11869646.

5: van Veldhuisen DJ, Poole-Wilson PA. The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure. Int J Cardiol. 2001 Aug;80(1):19-27. Review. PubMed PMID: 11532543.

6: Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blocker use in patients with reversible airway disease. Cochrane Database Syst Rev. 2001;(2):CD002992. Review. Update in: Cochrane Database Syst Rev. 2002;(1):CD002992. PubMed PMID: 11406056.

7: Febo O, Cobelli F. [Exercise test in the evaluation of the efficacy of drug therapy]. Ital Heart J Suppl. 2000 Mar;1(3):393-9. Review. Italian. PubMed PMID: 10815269.

8: Carson PE. Beta-blocker therapy in heart failure: pathophysiology and clinical results. Curr Probl Cardiol. 1999 Jul;24(7):421-60. Review. PubMed PMID: 10403092.

9: Bonarjee VV, Dickstein K. Novel drugs and current therapeutic approaches in the treatment of heart failure. Drugs. 1996 Mar;51(3):347-58. Review. PubMed PMID: 8882374.

10: Shah R. CPMP note for guidance: clinical trials on the medicinal products in the treatment of cardiac failure. Methods Find Exp Clin Pharmacol. 1996;18 Suppl C:31-3. Review. PubMed PMID: 9003573.

11: Cruickshank JM. The xamoterol experience in the treatment of heart failure. Am J Cardiol. 1993 Mar 25;71(9):61C-64C. Review. PubMed PMID: 8465800.

12: Fowler MB. Controlled trials with beta blockers in heart failure: metoprolol as the prototype. Am J Cardiol. 1993 Mar 25;71(9):45C-53C. Review. PubMed PMID: 8096675.

13: Sørensen EV. Xamoterol--a beta-1-adrenoceptor partial agonist. Pharmacology and clinical use. Dan Med Bull. 1993 Mar;40(1):111-21. Review. PubMed PMID: 8472594.

14: MacFadyen RJ. Role of the circulating and tissue-based renin-angiotensin system in the development of heart failure: implications for therapy. Cardiology. 1993;83(1-2):38-48. Review. PubMed PMID: 8261485.

15: Widimský J, Cihák R. [Can pharmacotherapy in heart failure affect mortality?]. Vnitr Lek. 1992 Mar;38(3):209-19. Review. Czech. PubMed PMID: 1595210.

16: Hayashida W, Kumada T, Kawai C. [New oral drugs for the treatment of congestive heart failure]. Nihon Rinsho. 1992 Feb;50(2):413-9. Review. Japanese. PubMed PMID: 1319514.

17: Widimský J. Can pharmacological therapy influence the mortality of chronic congestive heart failure? Cor Vasa. 1992;34(1):15-30. Review. PubMed PMID: 1288941.

18: Johnson JA. Diastolic dysfunction in congestive heart failure. Clin Pharm. 1991 Nov;10(11):850-61. Review. PubMed PMID: 1794221.

19: Waller DG. Effect of drug treatment on quality of life in mild to moderate heart failure. Drug Saf. 1991 Jul-Aug;6(4):241-6. Review. PubMed PMID: 1888440.

20: Xamoterol--more trouble than it's worth? Drug Ther Bull. 1990 Jul 9;28(14):53-4. Review. PubMed PMID: 1983395.